ALK and non-small cell lung carcinoma: ALK inhibitors are now well accepted as frontline agents with efficacy for ALK positive NSCLC (Awad and Shaw, 2014), although duration of response is tempered by the emergence of therapy resistant mutations (Choi et al., 2010; Doebele et al., 2012; Katayama et al., 2014, 2012).